Immunomedics: Corporate Presentation (Immunomedics) - May 7, 2016 - "IMMU-130: Efficacy in Metastatic Colorectal Cancer: Median PFS of 3.9 months and median OS of 6.7 months in 20 patients with prior treatment with regorafenib, bevacizumab, 5-fluorouracil, irinotecan and oxaliplatin-containing chemotherapies"
P1/2 data • Colorectal Cancer • Oncology
|